INAMRINONE SUMMARY
INAMRINONE INJECTION USP
Inamrinone Injection USP represents a new class of cardiac inotropic agents distinct from digitalis glycosides or catecholamines.
Inamrinone (inamrinone) is indicated for the following:
Inamrinone injection is for the short-term management of congestive heart failure. Because of limited experience and potential for serious adverse effects (see ADVERSE REACTIONS), inamrinone should be used only in patients who can be closely monitored and who have not responded adequately to digitalis, diuretics, and/or vasodilators. Experience with intravenous inamrinone in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions.
Whether given orally, continuously intravenously, or intermittently intravenously, neither inamrinone nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents (including inamrinone), symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk.
|
